Quick Answer
Armata Pharmaceuticals, Inc. reported Net Income Loss of -$173.80 million for the year ending 2025.
- Armata Pharmaceuticals, Inc. showed a decrease of -818.8% in Net Income Loss from 2024 to 2025.
- This data is from Armata Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Armata Pharmaceuticals, Inc.'s Net Income Loss has declined by 169.1%.
- Historical annual values: Fiscal year 2025: -$173.80 million | Fiscal year 2024: -$18.92 million | Fiscal year 2023: -$69.05 million | Fiscal year 2022: -$36.92 million | Fiscal year 2021: -$23.16 million | Fiscal year 2020: -$22.18 million | Fiscal year 2019: -$19.48 million | Fiscal year 2018: -$16.70 million | Fiscal year 2017: -$12.84 million | Fiscal year 2016: -$18.84 million | Fiscal year 2015: -$516.0 thousand | Fiscal year 2014: $23.11 million | Fiscal year 2013: -$64.58 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: